Litcius/Paper detail

LBA49 Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study

Edward B. Garon, Melissa L. Johnson, Aaron Lisberg, Alexander I. Spira, Noboru Yamamoto, Rebecca S. Heist, Jacob Sands, Kiyotaka Yoh, Funda Meric‐Bernstam, Satoru Kitazono, Jon Greenberg, F. Kobayashi, Yui Kawasaki, Lori Jukofsky, K. Nakamura, Toshio Shimizu

2021Annals of Oncology30 citationsDOIOpen Access PDF

Topics & Concepts

MedicineOncologynon-small cell lung cancer (NSCLC)Internal medicineLungLung cancerCancer researchA549 cellLung Cancer Treatments and MutationsLung Cancer Research StudiesCancer therapeutics and mechanisms
LBA49 Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study | Litcius